ATE420361T1 - Marker für therapie mit antidepressiva und damit in zusammenhang stehende verfahren - Google Patents

Marker für therapie mit antidepressiva und damit in zusammenhang stehende verfahren

Info

Publication number
ATE420361T1
ATE420361T1 AT01955013T AT01955013T ATE420361T1 AT E420361 T1 ATE420361 T1 AT E420361T1 AT 01955013 T AT01955013 T AT 01955013T AT 01955013 T AT01955013 T AT 01955013T AT E420361 T1 ATE420361 T1 AT E420361T1
Authority
AT
Austria
Prior art keywords
gsα
antidepressants
markers
therapy
related procedures
Prior art date
Application number
AT01955013T
Other languages
English (en)
Inventor
Mark Rasenick
Robert J Donati
Sadamu Toki
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE420361T1 publication Critical patent/ATE420361T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01955013T 2000-07-29 2001-07-30 Marker für therapie mit antidepressiva und damit in zusammenhang stehende verfahren ATE420361T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22187400P 2000-07-29 2000-07-29

Publications (1)

Publication Number Publication Date
ATE420361T1 true ATE420361T1 (de) 2009-01-15

Family

ID=22829768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01955013T ATE420361T1 (de) 2000-07-29 2001-07-30 Marker für therapie mit antidepressiva und damit in zusammenhang stehende verfahren

Country Status (7)

Country Link
US (4) US6875566B2 (de)
EP (1) EP1356292B1 (de)
AT (1) ATE420361T1 (de)
AU (2) AU7722201A (de)
CA (1) CA2417578C (de)
DE (1) DE60137368D1 (de)
WO (1) WO2002010763A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137368D1 (de) * 2000-07-29 2009-02-26 Univ Illinois Marker für therapie mit antidepressiva und damit in zusammenhang stehende verfahren
FR3078463A1 (fr) 2018-02-26 2019-08-30 Stmicroelectronics (Rousset) Sas Procede et dispositif de realisation d'operations en table de substitution
US11218291B2 (en) 2018-02-26 2022-01-04 Stmicroelectronics (Rousset) Sas Method and circuit for performing a substitution operation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034071A (en) * 1994-09-16 2000-03-07 Iyengar; Srinivas Ravi V. Mutant activated GS α and adenylyl cyclase 2 for use as therapeutic agents
US6107076A (en) * 1995-10-04 2000-08-22 Board Of Regents, The University Of Texas System Soluble mammalian adenylyl cyclase and uses therefor
IL116205A0 (en) * 1995-11-30 1996-01-31 Univ Ben Gurion Methods and kits for diagnosis and monitoring treatments of psychiatric disorders
US6071722A (en) * 1998-04-24 2000-06-06 Smithkline Beecham Corporation Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1)
US20020061599A1 (en) * 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
DE60137368D1 (de) * 2000-07-29 2009-02-26 Univ Illinois Marker für therapie mit antidepressiva und damit in zusammenhang stehende verfahren
US6448377B1 (en) * 2000-09-27 2002-09-10 The Board Of Trustees Of The Leland Stanford Junior University Modified G protein sunbunits
US20040209808A1 (en) * 2003-02-11 2004-10-21 Kornacker Michael G. Modulators of human G-protein coupled receptors

Also Published As

Publication number Publication date
AU2001277222B2 (en) 2006-05-04
USRE43712E1 (en) 2012-10-02
US7445888B2 (en) 2008-11-04
DE60137368D1 (de) 2009-02-26
CA2417578C (en) 2008-07-15
US6875566B2 (en) 2005-04-05
WO2002010763A2 (en) 2002-02-07
US7118858B2 (en) 2006-10-10
WO2002010763A3 (en) 2003-08-28
US20050153388A1 (en) 2005-07-14
EP1356292A2 (de) 2003-10-29
US20070026385A1 (en) 2007-02-01
AU7722201A (en) 2002-02-13
US20020039752A1 (en) 2002-04-04
CA2417578A1 (en) 2002-02-07
EP1356292B1 (de) 2009-01-07

Similar Documents

Publication Publication Date Title
DE60238058D1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
ATE469219T1 (de) Zusammensetzungen, methoden und reagentien zur nukleinsäureisolierung mittels oberflächenaktiven substanzen und proteasen
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
HK1083366A1 (en) Diagnosing tumorigenicity and determining resistance to anticancer therapy
DE60012716D1 (de) Neue halbleiternanopartikel zur analyse von blutzellpopulationen
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DK1019082T3 (da) Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
EP1619206A3 (de) Gewebeinhibitor der Matrix-Metalproteinase Typ 1 (TIMP-1) als Krebsmarker
DE59912716D1 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
DE60041278D1 (de) Amplifizierung von cyp24 und anwendung dafür
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
ATE388223T1 (de) Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
ATE420361T1 (de) Marker für therapie mit antidepressiva und damit in zusammenhang stehende verfahren
DE60012140D1 (de) Verwendung von urintrypsininhibitor zur diagnose von aids
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
DE69913533D1 (de) Reagentien für cyp2d fluoreszenztest
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
DE60225168D1 (de) Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür
DE60327710D1 (de) Modifizierte zytokine für krebs therapie
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
ATE470856T1 (de) Gleichzeitigen flusszytometrischer messungen von die inhibition der zellproliferation und der toxizität
ATE274920T1 (de) Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
ATE208504T1 (de) Komplex-gebundene hemmstoffe aktivierbarer stoffwechselenzyme als molekulare marker zur diagnostik und therapieüberwachung
ATE423321T1 (de) Verfahren zur detektion von prpsc unter verwendung von gruppe ii aminoglykosid antibiotika

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties